This event is archived.

À propos

La Société Canadienne d'Insuffisance Cardiaque vous invite à vous joindre à deux experts de renommée mondiale pour une discussion approfondie de la prise en charge de l'hyperkaliémie chez les patients avec insuffisance cardiaque (IC). L'hyperkaliémie est de plus en plus répandue chez les patients avec IC, puisqu’un nombre grandissant de cette population vivent avec des maladies concomitantes telles que le diabète et l'insuffisance rénale chronique. L'arrêt des inhibiteurs de la rénine-angiotensine-aldostérone (iSRAA) pour gérer l'hyperkaliémie peut entraîner des risques, car les iSRAA sont un élément clé du traitement clinique de l'IC. Les experts discuteront de la définition de l'hyperkaliémie, ainsi que des données et des meilleures pratiques sur le traitement de l'hyperkaliémie sans interrompre le traitement iSRAA.

Objectifs d'apprentissage

1.      Reconnaître que l’hyperkaliémie est un obstacle au traitement optimal des inhibiteurs du système rénine-angiotensine aldostérone (iSRAA) et ses impacts sur les patients

2.      Définir les lacunes des soins cliniques dans le traitement d’hyperkaliémie chronique

3.      Comprendre les avantages des nouveaux liants de potassium pour optimiser l’utilisation des thérapies d’iSRAA

Orateurs

Présidente

  • Anique Ducharme MD, MSc, FRCP
    Dr. Anique Ducharme is a Professor of Medicine at Université de Montréal and holds the University of Montreal Fondation Marcelle and Jean Coutu, Cal & Janine Moisan for better practices in advanced heart failure. She is also the founder and Director of the Heart Failure Clinic at the Montreal Heart Institute (MHI) and a former Senior Clinical Researcher at the Fonds québécois de recherche en santé (FQRS). She is president of the Canadian Heart Failure Society (CHFS) and the past chair of the Scientific Program Committee for the Canadian Cardiovascular Congress (2018-2020). In addition, she is an active member of the CCS Heart Failure Guidelines Committee, sitting on the primary panel since 2006.
    Dr. Ducharme graduated from Université de Montréal in 1991 in Medicine (MD) and Biomedical sciences (MSc, cardiac transplantation) and completed her residency in Cardiology in 1996. She pursued additional training in Echocardiography at the Montreal Heart Institute, then in Molecular Biology and Heart Failure at the Brigham & Women’s Hospital, Harvard Medical School in Boston. Since her return in 1999, she has held a position in the Noninvasive Cardiology department at the Montreal Heart Institute, where she carries out activities in echocardiography, advanced heart failure and cardiac transplantation. Her clinical and research focus is on advanced heart failure, including remodeling, pharmacological and device therapies (cardiac resynchronization therapy, mechanical assist devices and transplantation).
    Dr. Ducharme has published over 150 peer-reviewed articles, 15 book chapters, 200 abstracts and 2 online university tutorial courses (Echocardiography Certificate, University of Melbourne, Australia).
    She is currently PI for the SELFIE (Virtual HF clinic) and the CHAMP trials, and has sat on the executive committee of the CANSAVER and EARTH studies. Dr. Ducharme has served on several steering committees for large-scale studies, including GUIDE-HF, STICH, AF-CHF, EARTH, RELAX-HF and CHARM. She also participates in several review panels for journals, including Circulation, the Journal of the American College of Cardiology, the Journal of Cardiac Failure, the Canadian Medical Association Journal and the Canadian Journal of Cardiology.

Conférencier

  • Patrick Rossignol MD, PhD

    Patrick Rossignol, MD, PhD, is a Nephrologist and Vascular medicine specialist, European Society of Hypertension certified hypertension specialist, Professor of Therapeutics at the University of Lorraine, France.

    ·        Since 2007, he was holding the position of deputy Director of the Nancy University Hospital Inserm Clinical Investigation Centre, which was headed by Professor Faiez Zannad. Patrick Rossignol is heading the Centre since January 2018.

    ·        Since 2014, he is coordinating a French multidisciplinary (basic researchers, cardiologists, nephrologists, intensivists, epidemiologists, geriatricians, GPs) network of excellence endorsed by the “Investissement d’Avenir” F-CRIN (French Clinical research Infrastructure Network, the French affiliate of ECRIN/ERIC: Cardiovascular and Renal Clinical Trialists (INI-CRCT) www.inicrct.org. As such, he is coordinating the INSERM cardiovascular clinical Investigation centres, a component of INI-CRCT, and is serving in F-CRIN steering committee. Since 2019, he is serving in F-CRIN executive board.

    ·        He is a Researcher in Inserm U1116, he runs outpatient clinics at the Nancy University Hospital Heart Failure and Hypertension Unit (ESH excellence Centre) as well as in a hemodialysis clinic within a Disease Management programme (ALTIR).

Sponsor

  • Otsuka Canada Pharmaceutical Inc.